

Dated: June 3, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E8-12880 Filed 6-6-08; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### **Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Evaluation of Environmental and Policy Interventions To Increase Fruit and Vegetable Intake, Potential Extramural Project 2008-R-11**

*Correction:* This notice was published in the **Federal Register** on April 21, 2008, Volume 73, Number 77, page 21355. The aforementioned meeting has been rescheduled to the following:

*Time and Date:* 1 p.m.–3 p.m., June 11, 2008 (Closed).

*Contact Person for More Information:* Linda Shelton, Program Specialist, Coordinating Center for Health and Information Service, Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21, Atlanta, GA 30333. Telephone (404) 498-1194.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 3, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E8-12882 Filed 6-6-08; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### **Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: A Retrospective Evaluation of Patterns of Care for American Indian and Alaska Native Men With Elevated Prostate Specific Antigen, Potential Extramural Project 2008-R-15**

*Correction:* This notice was published in the **Federal Register** on April 18, 2008, Volume 73, Number 76, page 21137. The aforementioned meeting has been rescheduled to the following:

*Time and Date:* 1 p.m.–3 p.m., June 11, 2008 (Closed).

*Contact Person for More Information:* Linda Shelton, Program Specialist, Coordinating Center for Health and Information Service, Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21, Atlanta, GA 30333. Telephone (404) 498-1194.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 3, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E8-12889 Filed 6-6-08; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### **National Center for Injury Prevention and Control (NCIPC) Advisory Committee for Injury Prevention and Control (ACIPC)**

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC), announces the following subcommittee and committee meetings:

*Name:* Science and Program Review Subcommittee (SPRS).

*Time and Date:* 10:30 a.m.–12:30 p.m., June 25, 2008.

*Place:* The teleconference will originate at CDC, 4770 Buford Highway, NE., Building 106, Ninth Floor, Room 108E, Atlanta,

Georgia 30341. To participate, dial (877) 934-7121 and enter conference code 8396688.

*Status:* Open: 10:30 a.m.–10:45 a.m., June 25, 2008. Closed: 10:45 a.m.–12:30 p.m., June 25, 2008.

*Purpose:* The Science and Program Review Subcommittee provides advice on the needs, structure, progress and performance of programs of the National Center for Injury Prevention and Control.

*Matters To Be Discussed:* The subcommittee will meet June 25, 2008, to provide a secondary review of, discuss, and evaluate the individual research grant and cooperative agreement applications submitted in response to Fiscal Year 2008. Requests for Applications (RFAs) related to the following individual research announcements: 08001, Youth Violence through Community-Level Change; 08002, Grants for Traumatic Injury Biomechanics and their Severity; 08003, Research for Prevention Violence and Violence Related Injury; 08004, Translation Research to Prevent Motor Vehicle-Related Crashes and Injuries to Teen Drivers and Their Passengers; 08005, Dissertation Grant Awards for Doctoral Candidates for Violence-Related Injury Prevention Research in Minority Communities; 08006, Feasibility of Acute Concussion Management in the Emergency Department; and 08007, Assessing the Effects of Interpersonal Violence Prevention on Suicide. The applications being reviewed include information of a confidential nature, including personal and financial information concerning individuals associated with the applications. Following this meeting, the voting members of ACIPC will meet via teleconference to vote on the recommendations of the SPRS regarding the RFAs. This conference call will take place on June 27, 2008.

*Name:* Advisory Committee for Injury Prevention and Control.

*Time and Date:* 11:30 a.m.–12:30 p.m., June 27, 2008.

*Place:* The teleconference will originate at CDC, 4770 Buford Highway, NE., Building 106, Sixth Floor, Room 6A, Atlanta, Georgia 30341. To participate, dial (877) 934-7121 and enter conference code 8396688.

*Status:* Open: 11:30 a.m.–11:55 a.m., June 27, 2008. Closed: 11:55 a.m.–12:30 p.m., June 27, 2008.

*Purpose:* The committee advises and makes recommendations to the Secretary, Department of Health and Human Services, the Director, Centers for Disease Control and Prevention, and the Director, National Centers for Injury Prevention and Control regarding feasible goals for the prevention and control of injury. The committee makes recommendations regarding policies, strategies, objectives, and priorities, and reviews progress toward injury prevention and control.

*Matters To Be Discussed:* Agenda items for the open portion include the call to order and introductions and request for public comments. The Committee will vote on the results of the secondary review. The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(4) and (b), title 5 U.S.C., and the Determination of the Director, Management

Analysis and Services Office, CDC pursuant to Public Law 92-463. Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Ms. Amy Harris, Executive Secretary, ACIPC, NCIPC, CDC, 4770 Buford Highway, NE., M/S F-63, Atlanta, Georgia 30341-3724, telephone (770) 488-4936.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 3, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E8-12892 Filed 6-6-08; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Safety and Occupational Health Study Section (SOHSS), National Institute for Occupational Safety and Health, (NIOSH)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned committee:

##### *Times and Dates:*

8 a.m.-5 p.m., June 26, 2008 (Closed);

8 a.m.-5 p.m., June 27, 2008 (Closed).

*Place:* Embassy Suites Hotel, 1900

Diagonal Road, Alexandria, Virginia 22314, Telephone (703) 684-5900, Fax (703) 684-1403.

*Purpose:* The Safety and Occupational Health Study Section will review, discuss, and evaluate grant application(s) received in response to the Institute's standard grants review and funding cycles pertaining to research issues in occupational safety and health, and allied areas.

It is the intent of NIOSH to support broad-based research endeavors in keeping with the Institute's program goals. This will lead to improved understanding and appreciation for the magnitude of the aggregate health burden associated with occupational injuries and illnesses, as well as to support more focused research projects, which will lead to improvements in the delivery of occupational safety and health services, and the prevention of work-related injury and illness. It is anticipated that research funded will promote these program goals.

These portions of the meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and

Services Office, Centers for Disease Control and Prevention, pursuant to Section 10(d) Public Law 92-463.

*Matters To Be Discussed:* The meeting will convene to address matters related to the conduct of Study Section business and to consider Safety and Occupational Health-Related Grant Applications.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Price Connor, PhD, NIOSH Health Scientist, 1600 Clifton Road, NE., Mailstop E-20, Atlanta, Georgia 30333, Telephone (404) 498-2511, Fax (404) 498-2571.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: May 30, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E8-12793 Filed 6-6-08; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Notice of Approval of Supplemental New Animal Drug Application; Moxidectin

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is providing notice that it has approved a supplemental new animal drug application (NADA) filed by Fort Dodge Animal Health, Division of Wyeth. The approved NADA provides for the veterinary prescription use of a sustained-release injectable moxidectin formulation for prevention of heartworm disease and treatment of existing hookworm infections in dogs. The supplemental NADA adds animal safety information to product labeling.

**FOR FURTHER INFORMATION CONTACT:** Melanie R. Berson, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8337, e-mail: [melanie.berson@fda.hhs.gov](mailto:melanie.berson@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Fort Dodge Animal Health, Division of Wyeth, 800 Fifth St. NW., Fort Dodge, IA 50501, filed a supplement to NADA 141-189 that provides for veterinary prescription use of PROHEART 6 (moxidectin) Sustained Release

Injectable for Dogs, used for prevention of heartworm disease and treatment of existing hookworm infections. The supplemental NADA updates the warning, precaution, adverse reactions, and post-approval experience sections of product labeling. In accordance with section 512(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(i)) and 21 CFR 514.105(a) and 514.106(a), the Center for Veterinary Medicine is providing notice that this supplemental NADA is approved as of May 23, 2008.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(d)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: June 2, 2008.

**Bernadette Dunham,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 08-1329 Filed 6-5-08; 12:00 pm]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Cardiovascular and Renal Drugs Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on June 25, 2008, from 8 a.m. to 5 p.m.

*Location:* Hilton Washington DC/ Silver Spring, Maryland Ballroom, 8727